Replies to post #90734 on Biotech Values

[DewDiligence]

IDIX Major Shareholders

[Updated for NVS’ small “true-up” purchase‡ on 2/26/10.]


The percentages shown below are based on 71M diluted shares for valuation purposes
(#msg-40353178), and hence they differ from the percentages reported in SEC filings.

 
                      Shares    Stake 
 Novartis           31,320,964  44.2% 
 JP Sommadossi (CEO) 4,226,000*  6.0% 
 BB/MPM Capital      3,321,534†  4.7% 
 GlaxoSmithKline     2,474,527   3.5% 

*Includes all of Sommadossi’s 2.2M options, whether or not vested.
†As of 12/31/09.
‡NVS has the contractual right to make small “true up” purchases from time to time to offset option exercises by IDIX’s employees and thereby maintain a constant equity stake. The price paid by NVS for these shares is the average exercise price of the small number of options in question.